Patients with hepatitis C virus( HCV)-related cirrhosis are at a higher risk for the development of hepatic failure and hepatocellular carcinoma( HCC) compared with non-cirrhotic patients. Antiviral therapies for HCV-related cirrhosis may reduce the incidence of HCC and hepatic failure. This article introduces current antiviral therapies for HCV-related cirrhosis: P / R,DAA + P / R,and IFN-free regimens,and summarizes the present situation of antiviral therapies for HCV-related cirrhosis. It is thought that the advent of direct-acting antivirals has improved the rate of sustained virologic response and reduced the incidence of adverse events during the treatment of HCV-related cirrhosis. Interferon-free regimens have great advantage and potential in antiviral therapies for HCV-related cirrhosis.
DownLoad: